Atrial natriuretic peptide (ANP) specifically stimulates particulate guanylate cyclase, and cyclic guanosine monophosphate (cGMP) has been recognized as its second messenger. Spontaneously hypertensive rats (SHR) have elevated plasma ANP levels, but manifest an exaggerated natriuretic and diuretic response to exogenous ANP when compared to normotensive strains. In isolated glomeruli, the maximal cGMP response to ANP corresponds to a 12-to 14-fold increase over basal levels in normotensive strains (Wistar 13±2; Wistar-Kyoto 12+2;
Introduction
Atrial natriuretic peptide (ANP),' a hormone synthesized in specific granules of the heart, elicits multiple physiological responses apparently mediated via cyclic GMP (cGMP; for review, see references [1] [2] [3] [4] [5] . Some of its most striking biological effects are the natriuresis and diuresis it produces. Despite numerous investigations of its renal mechanisms of action, the exact processes involved are still not fully understood. High concentrations of particulate guanylate cyclase and cGMP levels elevated by ANP have been noted in glomeruli (6) (7) (8) (9) , which possess an abundance of specific ANP receptors (6, (10) (11) (12) (13) (14) .
The existence of distinct ANP binding sites has been demonstrated (15) (16) (17) . The larger( 130-kD) ANP receptor type is a glycoprotein linked to particulate guanylate cyclase with rigorous binding specificity (18) (19) (20) (21) ). Isolation, sequencing, cloning, and expression of the protein from various species have shown that guanylate cyclase is an integral part of the molecule (22) (23) (24) (25) . Two subtypes of guanylate cyclase-related receptors (ANP-A and ANP-B receptors) have been cloned with different ligand binding affinities despite overall structural homology (24, 26, 27) . Elucidation of the gene structure of the ANP A-receptor, responding preferentially to ANP, has been achieved (28) . Both receptor subtypes have a large extracellular NH2-terminal domain, a putative single membrane spanning sequence and an intracellular region containing both a putative kinase-like regulatory domain required for signalling via ANP (29) , and a guanylate cyclase catalytic domain (24, 25) responsible for synthesis of cGMP, the effector of ANP. Another receptor type, known as the C-receptor, has a molecular mass of 120 kD on SDS-PAGE and can be reduced to 65 kD with ,B-mercaptoethanol (30). It has a high affinity for the ligand and is widely distributed (30). This truncated homodimeric glycoprotein has only 37 amino acids for its intracellular domain (30) and is therefore not linked to catalytic guanylate cyclase activity (20, 30) . Its role as a clearance or buffer receptor ( 31 ) is closely related to internalization of the receptor-ligand complex, recycling and hydrolyzing ANP (32). However, the down-regulation ofANP receptors may require prior ANPguanylate cyclase receptor occupancy (33) .
ANP has been postulated to play a role in the development of arterial hypertension and in the counterregulation of increased blood pressure. There are many reports of elevated plasma ANP levels in human essential hypertension (34) (35) (36) (37) (38) , even in correlation with the extent of left ventricular and auri-cular abnormalities (39), and also in healthy young people with a family history of hypertension as well as in SHR (40) (41) (42) (43) (44) . Plasma ANP levels have been reported to be increased in different forms of experimental hypertension (45) (46) (47) (48) . However, some authors have not found elevated ANP levels in patients with mild, age-adjusted hypertension (49) (50) (51) or in young SHR (52) . Down-regulation of ANP receptors has been reported in vitro in vessels as well as in cultured smooth muscle cells, contrasting with normal or even increased cGMP production (53) (54) (55) (56) (57) . No difference in receptor density or affinity is observed in glomeruli of young SHR (58, 59) , while older animals with heightened blood pressure reportedly demonstrate a reduced receptor population (59, 60) . Changes occur in other organ systems as well (44, 61, 62) . Furthermore, the number ofbinding sites is modified by alterations in blood pressure. Data on binding affinity in these studies are conflicting. In other models of experimental hypertension, binding affinity is increased in the early hypertensive phase (63) , while receptor density is unchanged or diminished in later periods (45, 47, 48, 64) .
Since hypertensive animals appear to have normal to elevated endogenous plasma ANP levels with decreased binding capacity, it is surprising that ANP infusions have an increased or prolonged effect on diuresis, natriuresis, and blood pressure in hypertensive rats and monkeys (65-69) as well as in humans with essential hypertension (70) (71) (72) . We therefore evaluated the ANP response of guanylate cyclase in normotensive rats and SHR in studies aimed at elucidating its mechanism in this model of hypertension.
Methods
Materials. Male rats obtained from Taconic Farms Inc., Germantown, NY (WKY, SHR), Charles River, St-Constant, Que., Canada, and Harlan Sprague Dawley Inc., Indianapolis, IN, were kept at room temperature under a 12 h:12 h dark/light cycle. They were fed normal Purina rat chow and allowed free access to tap water. Synthetic rat ANP 9-'26 and leupeptin were purchased from Institut Armand-Frappier, Laval, Que., Canada. C-ANP'02'21-des[Gln"6, Ser'7, Gly'8, Leu 119, Gly'20]ANP-NH2 (C-ANP) was generously donated by BioMega, Chomedey, Laval, Que., Canada. Carrier-free 1251I-Na was acquired from Amersham Corp., Oakville, Ont., Canada; disuccinimidyl suberate (DSS) and Triton X-100 were procured from Pierce, Rockford, IL, USA. Electrophoresis reagents and molecular weight standards were obtained from Bio-Rad, Mississauga, Ont., Canada. Lactoperoxidase and bovine gamma-globulin came from Sigma, St. Louis, MO.
Tissue preparations. Male rats were decapitated between 8 to 10 a.m. to exclude a possible effect of diurnal variations. Their kidneys were rapidly removed and placed in gas-modified (95% 02/5% C02) Krebs solution, pH 7.4, at 4VC. The cortex was separated, cut into slices, and gently ground successively through 250-and 1 50-,m molecular sieves. The pass-through fraction was washed three times with Krebs solution on a 70-,gm mesh. The supernatant was then centrifuged three times at 400 g for 3 min. The purity of the suspensions, verified by phase contrast microscopy, was over 95%. Protein concentrations of glomerular preparations were measured by the method described by Lowry et al. (73) .
Whole lungs and livers were also removed, while the renal papilla and zona glomerulosa were dissected from the kidney and adrenal cortex respectively. The tissues were homogenized with a Potter-Elvehjem homogenizer for large preparations or with a Dounce homogenizer for smaller samples in 5 vols of ice-cold 50 mM Hepes buffer, pH 7.4, containing 1 mM EDTA, 10 Mg/ml leupeptin, and 0.1 mM PMSF.
After centrifugation at 30,000 g for 30 min, the pellets were resuspended and centrifuged a second time. Washed pellets were resuspended in the same buffer at a protein concentration of -20 mg/ml.
Stimulation of cGMP production in glomeruli. Isolated glomeruli (6) in the amount of 400-500 Mg were incubated in 400 Ml Krebs solution for 15 min at 370C and for 2 additional min with 500 MM of the phosphodiesterase inhibitor, methylisobutylxanthine (MIX; reference 9). Acetic acid (0.01 N) or increasing concentrations of ANP( 10-'0to 10-6 M) were then added. The reaction was stopped after 90 s with IN perchloric acid. The samples were rapidly frozen in liquid nitrogen and kept at -350C until sonication, extraction, and cGMP measurement by RIA, as described previously (74, 75) .
Solubilization ofmembranes. Glomeruli and papilla were isolated as described above. For binding and crosslinking studies, the membrane fractions were solubilized with 3% Triton X-100 for 60 min at 4VC in 50 mM Hepes buffer, pH 7.4, containing 1 mM EDTA, 50
Mg/ml leupeptin, 0.1 mM PMSF, and 0.6 M KC1. The samples were then centrifuged at 105,000 g for 30 min and resuspended in the same buffer. Protein content was measured by Peterson's method (76) .
Receptor binding assay. ANP9'26 was iodinated with 1 mCi of '25I-labeled Na by the lactoperoxidase method and purified by HPLC on a C 1&u-Bondapak column, as described previously (77) . For ANP binding assay, glomeruli were isolated and membranes solubilized as detailed above. Briefly, 50 MAg of protein were incubated with '25I-labeled ANP (10,000 cpm) for 60 min at 22°C in 100 mM phosphate buffer, pH 7.4, 10 Mg/ml aprotinin, 10 Mg/ml leupeptin, 5 mM MgCl2, 0.5 mM PMSF, 0.4% BSA and 0.1% Triton X-100 in the absence or presence of increasing concentrations of cold ANP99 '26 or C-ANP102-'2' in a final volume of 100 Ml. Nonspecific binding was determined in the presence of I AM of unlabeled ANP '126. At the end of incubation, 25 Ml of bovine gamma-globulin (0.3%) and I ml of polyethyleneglycol (PEG; 16%) in phosphate buffer, pH 7.4, were added. The incubation mixture was immediately poured onto polyethylenimine-treated (0.3%, 30 min) Whatman GF/C fiberglass filters, rinsed three times with I ml PEG, and its radioactivity was counted with a Gamma counter.
Affinity cross-linking with '25I-ANP. Triton X-100-solubilized glomerular or papillar proteins (500 Mg) were incubated with 0.1 nM 251-labeled ANP (5 X 106 cpm) for 60 min at 22°C in I ml of sodium phosphate buffer, pH 7.4, containing 0.1 mM PMSF, 10 Mg/ml aprotinin, 10 Mg/ml leupeptin, and 5 mM MgCl2 in the absence or presence of 0.1 MM unlabeled C-ANP 102-121 or ANP '26. After incubation, the protein-bound radioactivity was isolated by gel filtration on Sephadex G-50 (0.5 X 14 cm), and the cross-linking reagent DSS was added at a final concentration of 0.5 mM and incubated for 15 min at 22°C. The final reaction was quenched by 50 mM ammonium acetate. Bound 1251-labeled ANP was detected by autoradiography after SDS-PAGE.
Guanylate cyclase assay. Particulate guanylate cyclase activity was measured in membranes of various tissues, as described previously (78) . The reaction mixture (0.1 ml) contained 9.25 mg/ml phosphocreatine, 2.5 mg/ml creatine phosphokinase, 2 mM MIX, 10mM theophylline, 3 mM excess MnCI2, 1 mM GTP-MnCI2, and 50 mM triethanolamine buffer, pH 7.4, in the absence or presence of 1 MM ANP.
Membrane proteins or solubilized preparations were added, incubated at 37°C for 30 min, and the reaction was stopped with 2 ml of 30 mM hot EDTA. cGMP formed was measured by radioimmunoassay (74, 75) .
Radiation-inactivation. Pulmonary membrane preparations were brought to 2 mg/ml of proteins and pre-incubated at 4°C for 10 min with 0.01 N acetic acid or with 0.5MM ANP, a dose which was shown in pilot experiments to fully activate guanylate cyclase. Control and ANPtreated samples were quickly aliquoted into Eppendorf tubes (200 ,l) and rapidly frozen in liquid nitrogen. Samples kept at -780C with dry ice at exposure times varying between 0 and 24 h were irradiated in a Gammacell 220 irradiator (Atomic Energy of Canada Ltd., Ottawa, Ont., Canada) delivering a steady dose of about 1.35 Mrads/h (79) (80) (81) . Residual guanylate cyclase activity assessed on rapidly-thawed samples was plotted semilogarithmically as a function of radiation dose. A line passing near 2 (100% activity) at 0 radiation dose was constructed by least square analysis. The radiation-inactivation size (or RIS) of the functional unit studied was calculated by the equation log RIS = 5.89 -log D37 -0.0028t where D37 is the radiation dose needed to decrease the function of a protein to 37% of its initial value (82) and t is the temperature during radiation (83) .
Quantitative measurement ofANP A-and B-receptor mRNA transcripts, with regard to (a) preparation ofmutant ANPA-and B-receptor cDNA and cRNA. To clone a fragment of ANP A-receptor cDNA, total RNA from rat pituitaries was extracted and transcribed into cDNA with M-MLV reverse transcriptase (Bethesda Research Laboratories, Bethesda, MD) primed with random hexamers according to the manufacturer's protocol. A 709 bp fragment was generated by 30 cycles of polymerase chain reaction (PCR) in a thermocycler (Perkin Elmer Cetus, Norwalk, CT) as described below. The sense and antisense primers were respectively: GGAGAGAACACAAGCTTATCTGG-AGG and AAAGTCGACCCCGGGAGGTCAGCCTCGAGTGGC-TACA. The sense primer from base 2712 (84) contained a HindIII site (underlined) while the antisense primer from base 3404 was extended in 5' with two sites, Sal I and Sma I. Using these sites, the PCR fragment was cloned into the plasmid pSP72.
A Differences were considered to be significant at P < 0.05.
Results
Stimulation ofcGMP production by ANP in glomeruli ofnormotensive and hypertensive rats. cGMP production was measured in glomeruli after 90 s incubation with ANP99-'26 in three normotensive strains (WKY, Wistar, and Sprague-Dawley rats) and in SHR (Fig. 1) . Previous experiments had shown that cGMP increased maximally after a 90-s incubation period (6) . Basal cGMP levels were similar in all four strains. ANP concentrations lower than 10-10 M did not enhance cGMP generation over basal levels in glomeruli in any of these animals. At an ANP concentration of 10-' M, cGMP levels in normotensive strains rose between 50 and 80% while there was a 120% elevation in hypertensive animals. At higher ANP concentrations, cGMP levels increased more than 33-fold in SHR, while in the normotensive strains, they did not exceed a 15-fold augmentation (Wistar 13±2; Wistar-Kyoto 12±2; SpragueDawley 14±2). ANOVA established that the difference between the normotensive and hypertensive strains was highly significant (P < 0.001 ) whereas cGMP elevations in glomeruli Genetic heterogeneity has been demonstrated between animals from different commercial sources (86) . We therefore evaluated the effect of a maximal dose of ANP (1 gM) on cGMP levels in isolated glomeruli from SHR and WKY originating from three major commercial sources in North America. Our results showed that the phenotype of the glomerular cGMP response to ANP was well conserved and that a 2-to 3-fold difference was observed in the glomerular cGMP increase between WKY and SHR from the three commercial sources (Table I) . The difference between WKY and SHR preceded the phase of established hypertension. Thus, the fold increase of glomerular cGMP levels by ANP was 8 and 33 for WKY and SHR, respectively, at 6 wk ofage, 11 (Fig. 3) bound to the ANP C-receptor (Fig. 4) ( 15, 18) , affinity cross-linking in various tissues with '251-labeled ANP specifically labels 65-and 1 30-kD proteins. The high molecular weight form corresponds to the receptor containing particulate guanylate cyclase ( 15, 18) . The 65-kD protein is the ANP C-receptor that does not contain any intracellular catalytic activity. In glomeruli isolated from either WKY or SHR, both 130-and 65-kD proteins were labeled (Fig. 5 A, lanes I  and 4) . Only the 65-kD protein was competed for by C-ANP Guanylate cyclase activity. Guanylate cyclase activity was assessed directly in vitro in washed membranes prepared from various WKY and SHR organs (Table II) . Higher specific activity of particulate guanylate cyclase was found in membranes from the kidney papilla, adrenal cortex, and lungs, but not in the liver of SHR compared to WKY controls. When present, the greatest difference between WKY and SHR was observed for basal guanylate cyclase activity within its membrane environment. The difference between WKY and SHR decreased from basal to ANP-stimulated and Triton X-100-stimulated conditions, being least evident under the two latter conditions in the papilla and adrenal cortex. These results suggest that the basal specific activity of particulate guanylate cyclase within membranes of most organ systems is higher in SHR.
Radiation-inactivation. We attempted to characterize the behavior of the protein within its membrane environment in lung preparations from SHR and WKY by radiation-inactivation. This tissue source was chosen for its availability and similarity ofguanylate cyclase behavior to glomerular tissues under basal, ANP-, and detergent-enhanced conditions (Table II) . Under basal conditions, there is an activation hump in lung preparations from WKY and SHR rather than immediate destruction of enzymatic activity at doses up to 10 Mrads, followed by linear exponential decay. As reported previously (87, 88) , this pattern is best explained by the presence ofan intramolecular inhibitory component repressing guanylate cyclase activity in the basal state. ANP stimulation significantly enhanced guanylate cyclase decay by increasing doses of radiation in a monoexponential manner, most likely by liberating or deactivating the regulatory element (Fig. 6 ). Using the formula described in Methods, we calculated a RIS of 46 kD in both basal and ANP-stimulated states. The values did not differ significantly between WKY and SHR. These results indicate that ifthe guanylate cyclase domain in the protein within its natural environment, or following stimulation by the ligand, is any different in SHR, it is below the determination capability of this method.
Quantitative assay of ANP receptor subtype mRNAs by PCR-aided transcript titration. Total RNA from lung was used for the quantitation of ANP receptor mRNA. It can be seen from Table II and because mRNA for both receptors are more abundant in this organ (26) , it served as a source of RNA. Fig. 7 A shows a representative Phosphorlmager picture of PCR products from total lung RNA of WKY and SHR rats titrated with 2 x 101, 106, 5 x 106, 2 x 107 and 108 molecules of mutated cRNAs of ANP-A and ANP-B receptors. After digestion with EcoRI, DNA fragments of 315 and 394 bp (lower bands) for ANP A-receptor and of 378 and 387 bp for ANP B-receptor were generated by mutant cDNAs. Titration curves were constructed for ANP A-and ANP B-receptor mRNAs, using a fixed amount of lung total RNA mixed with increasing amounts of mutated cRNA (0.20 to 100 X 106 molecules) before reverse transcription and PCR (Fig. 7 B) . Percentages of 32P radioactivity following EcoRI digestion in the upper band vs. the sum of the upper and lower bands were calculated; a 50% value corresponded to the absolute amount of ANP A-or B-receptor mRNA molecules per ,ug of total RNA. It was of relevance to analyze the ratio of A and B receptor mRNAs within each strain as well as the relative expression of A and B receptor mRNAs in WKY and SHR, respectively. Thus, the ANP B-receptor mRNA level was about threefold higher than that ofANP A-receptor in WKY rats, while in SHR both receptors were equally represented (Fig. 7 C) . Furthermore, additional measurements in six different tissue preparations showed that ANP A-receptor mRNA levels were significantly higher in SHR than in WKY (P < 0.01), while the amount of mRNA of the ANP B-receptor was not significantly different between the two strains. In addition to Charles River SHR, these experiments were performed on rat strains from Taconic Farms with the same results.
Discussion
We report here a highly significant increase of cGMP production (about threefold) in response to ANP in glomeruli from SHR when compared to three normotensive rat strains. This phenotype is constant between SHR and WKY strains from three different suppliers and is present early in the life of SHR. Since blood pressure normalization does not affect this phenomenon, it has to be examined for its primary involvement in hypertension. As a first step, the present studies aimed at determining the mechanism of this increased cGMP production.
Data on ANP binding affinities and receptor densities are conflicting. Several authors have reported normal or diminished receptor density in glomeruli from SHR or in experimental hypertension (45, 48, (58) (59) (60) (24, 26, 30) . In glomeruli, we performed competitive displacement of 1251-labeled ANP with C-ANP, an agonist specific for the C-receptor (31 In summary, in SHR, overexpression of the ANP A-receptor subtype could explain the overproduction ofcGMP at basal levels. The abundance of the B-receptor over the A-receptor masked this overexpression in binding, cross-linking assays, and in total activation of guanylate cyclase by Triton X-100. Only precise mRNA quantitation of ANP receptor subtypes allowed the location ofthe difference between SHR and WKY.
It follows from our results that the abnormality in SHR should be observed only in tissues where the ANP A-receptor is expressed. In itself, this finding does not imply a primary pathogenetic role for this phenotype in the development ofhypertension, but provides a tool to test this role in gene transfection and transgenic studies currently under way.
